Database : MEDLINE
Search on : dialysis [Words]
References found : 166816 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 16682 go to page                         

  1 / 166816 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29514139
[Au] Autor:Kalantar-Zadeh K; Parameswaran V; Ficociello LH; Anderson L; Ofsthun NJ; Kwoh C; Mullon C; Kossmann RJ; Coyne DW
[Ad] Address:University of California Irvine, School of Medicine, Irvine, California, USA.
[Ti] Title:Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.
[So] Source:Am J Nephrol;47(3):153-161, 2018 Mar 07.
[Is] ISSN:1421-9670
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:BACKGROUND: A database analysis was conducted to assess the effectiveness of sucroferric oxyhydroxide (SO) on lowering serum phosphorus and phosphate binder (PB) pill burden among adult peritoneal dialysis (PD) patients prescribed SO as part of routine care. METHODS: Adult PD patients (n= 258) prescribed SO through a renal pharmacy service were analyzed. Baseline was 3 months before SO prescription. SO-treated follow-up was for 6 months or until either a new PB was prescribed, SO was not refilled, PD modality changed, or patient was discharged. In-range serum phosphorus was defined as ≤5.5 mg/dL. RESULTS: At baseline, mean serum phosphorus was 6.59 mg/dL with 10 prescribed PB pills/day. The proportion of patients achieving in-range serum phosphorus increased by 72% from baseline to month 6. Prescribed PB pills/day decreased by 57% (10 at baseline to 4.3 at SO follow-up, p< 0.0001). The mean length of SO follow-up was 5.1 months; SO follow-up ended for 38, 27, and 50 patients at months 4, 5, and 6, respectively, due to no further PB fills, and for 10, 11, and 4 patients at months 4, 5, and 6, respectively, due to another PB prescribed. In patients with baseline serum phosphorus >5.5 mg/dL who achieved in-range serum phosphorus during SO follow-up for ≥1 quarter, a notable improvement in serum phosphorus (6.54 to 5.10 mg/dL, p< 0.0001) was observed, and there was a 53% reduction in PB pill burden (9.9 to 4.7, p< 0.0001). CONCLUSION: Among PD patients prescribed SO as part of routine care, improvements in serum phosphorus control and >50% reduction in PB pills/day were observed.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:Publisher
[do] DOI:10.1159/000487856

  2 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29452187
[Au] Autor:Ijadi Bajestani M; Mousavi SM; Mousavi SB; Jafari A; Shojaosadati SA
[Ad] Address:Biotechnology Group, Chemical Engineering Department, Tarbiat Modares University, Tehran, Iran.
[Ti] Title:Purification of extra cellular poly-γ-glutamic acid as an antibacterial agent using anion exchange chromatography.
[So] Source:Int J Biol Macromol;113:142-149, 2018 Feb 13.
[Is] ISSN:1879-0003
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BLAST analysis of the 16S rRNA gene sequence for the newly isolated bacterium, revealed significant identity (99.5%) with Bacillus sonorensis [Ijadi Bajestani, M., et al., International Journal of Biological Macromolecules, 2017. 96: p. 100-110]. According to the literature review for closely related species of Bacillus sonorensis, the production of poly-γ-glutamic acid (γ-PGA) as an extra cellular biopolymer was investigated for the isolated bacteria which is deposited in IBRC (Iranian Biological Resource Center) as Bacillus sp. Strain M2 (IBRC-M11173). To determine if γ-PGA production by Bacillus sp. Strain M2 is glutamate dependent, it was grown on PGA medium, consisted of sodium glutamate. The results proved that γ-PGA production is highly dependent on glutamate component. In the following, the bioproduct has undergone different purification processes mainly consisting of dialysis, deproteinization and anion exchange chromatography. Based on the high-performance liquid chromatography (HPLC) results for ion chromatography effluents, 59% of the initial PGA in main solution was eluted via NaCl elution. Gel permeation chromatography (GPC) characterization analysis was accomplished to determine the polydispersity and γ-PGA molecular weight. Two major average molecular weights were distinguished; the heavy weight fraction of 7.710 g/mol with polydispersity index of 1.73 and the other one with an average molecular weight number of 1.710 g/mol and polydispersity index of 4.4. The antibacterial activity of the extracellular γ-PGA, as an anionic biopolymer, toward Staphylococcus aureus and E. coli, was assayed using the clinical and laboratory standards institute (CLSI) guidelines. For Staphylococcus aureus the minimum inhibitory concentration (MIC) value was about 34g/L while for E. coli this value reaches 53g/L.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  3 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29343519
[Au] Autor:Kolachalama VB; Shashar M; Alousi F; Shivanna S; Rijal K; Belghasem ME; Walker J; Matsuura S; Chang GH; Gibson CM; Dember LM; Francis JM; Ravid K; Chitalia VC
[Ad] Address:Section of Computational Biomedicine and.
[Ti] Title:Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans.
[So] Source:J Am Soc Nephrol;29(3):1063-1072, 2018 Mar.
[Is] ISSN:1533-3450
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Individuals with CKD are particularly predisposed to thrombosis after vascular injury. Using mouse models, we recently described indoxyl sulfate, a tryptophan metabolite retained in CKD and an activator of tissue factor (TF) through aryl hydrocarbon receptor (AHR) signaling, as an inducer of thrombosis across the CKD spectrum. However, the translation of findings from animal models to humans is often challenging. Here, we investigated the uremic solute-AHR-TF thrombosis axis in two human cohorts, using a targeted metabolomics approach to probe a set of tryptophan products and high-throughput assays to measure AHR and TF activity. Analysis of baseline serum samples was performed from 473 participants with advanced CKD from the Dialysis Access Consortium Clopidogrel Prevention of Early AV Fistula Thrombosis trial. Participants with subsequent arteriovenous thrombosis had significantly higher levels of indoxyl sulfate and kynurenine, another uremic solute, and greater activity of AHR and TF, than those without thrombosis. Pattern recognition analysis using the components of the thrombosis axis facilitated clustering of the thrombotic and nonthrombotic groups. We further validated these findings using 377 baseline samples from participants in the Thrombolysis in Myocardial Infarction II trial, many of whom had CKD stage 2-3. Mechanistic probing revealed that kynurenine enhances thrombosis after vascular injury in an animal model and regulates thrombosis in an AHR-dependent manner. This human validation of the solute-AHR-TF axis supports further studies probing its utility in risk stratification of patients with CKD and exploring its role in other diseases with heightened risk of thrombosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1681/ASN.2017080929

  4 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29270765
[Au] Autor:Hamano T
[Ad] Address:Department of Comprehensive Kidney Disease Research (CKDR), Osaka University Graduate School of Medicine, D11, 2-2 Yamadaoka, Suita, Osaka, Japan. hamatea@kid.med.osaka-u.ac.jp.
[Ti] Title:Vitamin D and renal outcome: the fourth outcome of CKD-MBD? Oshima Award Address 2015.
[So] Source:Clin Exp Nephrol;22(2):249-256, 2018 Apr.
[Is] ISSN:1437-7799
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:Bone fracture, cardiovascular events, and mortality are three outcomes of chronic kidney disease-mineral and bone disorder (CKD-MBD), and the umbrella concept originally described for dialysis patients. The reported association of serum phosphorus or fibroblast growth factor 23 (FGF23) levels with renal outcome suggests that the fourth relevant outcome of CKD-MBD in predialysis patients is renal outcome. We found that proteinuria of 2+ or greater with a dipstick test was associated with low vitamin D status due to urinary loss of 25-hydroxyvitamin D (25D). Moreover, active vitamin D or its analogues decrease proteinuria. Given our finding that maxacalcitol does not repress renin, the reduction of proteinuria by this agent is likely due to direct upregulation of the nephrin and podocin in podocytes. Moreover, this agent downregulates the mesenchymal marker desmin in podocytes and blocks transforming growth factor-beta autoinduction, leading to attenuation of renal fibrosis in a unilateral ureteral obstructive (UUO) model. These facts are reminiscent of the suppression of epithelial-mesenchymal transition (EMT) by vitamin D. EMT blockage may explain our finding that vitamin D prescription in renal transplant recipients is associated with a lower incidence of cancer. We also reported that low vitamin D status and high FGF23 levels predict a worse renal outcome. However, administration of massive doses of 25D exacerbates renal fibrosis in UUO kidneys in 1alpha-hydroxylase knockout mice. Moreover, FGF23 inhibits 1alpha-hydroxylase in proximal tubules and monocytes. Taken together, local 1,25(OH) D in the kidney tissue but not 25D seems to protect the kidney.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1712
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Process
[do] DOI:10.1007/s10157-017-1517-3

  5 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Clinical Trials Registry
Full text

[PMID]: 28741050
[Au] Autor:Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Kikuchi M; Shobu Y
[Ad] Address:Vanderbilt University School of Medicine, Nashville, TN, USA.
[Ti] Title:Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
[So] Source:Clin Exp Nephrol;22(2):299-308, 2018 Apr.
[Is] ISSN:1437-7799
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:BACKGROUND: Two randomized, double-blind, placebo-controlled trials (EPPIC-1 and EPPIC-2) investigated the efficacy and safety of AST-120, an oral spherical carbon adsorbent, in adults with chronic kidney disease (CKD). While the benefit of adding AST-120 to standard therapy was not supported by these trials, we performed a post hoc analysis to focus on CKD progression and to determine the risk factors for the primary endpoint in the EPPIC trial population. METHODS: In the EPPIC trials, patients were randomly assigned 1:1 to treatment with AST-120 or placebo. The primary endpoint was a composite of dialysis initiation, kidney transplantation, or doubling of serum creatinine. The EPPIC trial pooled population was evaluated with the same statistical methods used for analysis of the primary and secondary efficacy endpoints. The trials were registered on ClinicalTrials.gov (NCT00500682 [EPPIC-1] and NCT00501046 [EPPIC-2]). RESULTS: An analysis of the placebo population suggested baseline urinary protein to urinary creatinine ratio (UP/UCr) ≥1.0 and hematuria were independent risk factors for event occurrence and eGFR lowering. Analysis of the high risk patients revealed a difference in the primary endpoint occurrence between treatment groups, if angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers were administered (hazard ratio 0.74, 95% confidence interval 0.56-0.96). Also, the eGFR changes from baseline in the AST-120 group were smaller than that in the placebo group (P=0.035). CONCLUSIONS: CKD progression may have an association with baseline UP/UCr and hematuria. Treatment with AST-120 may delay the time to the primary endpoint in patients with progressive CKD receiving standard therapy, thus warranting further investigation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1707
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[Cl] Clinical Trial:ClinicalTrial
[St] Status:In-Process
[do] DOI:10.1007/s10157-017-1447-0

  6 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524080
[Au] Autor:Lee Loy J; Kamboj M; Koratala A
[Ad] Address:Division of Nephrology, Hypertension and Renal Transplantation, Department of Medicine, University of Florida, P.O. Box 100224, Gainesville, FL, 32610, USA.
[Ti] Title:A can't miss diagnosis for rash in a peritoneal dialysis patient.
[So] Source:Intern Emerg Med;, 2018 Mar 09.
[Is] ISSN:1970-9366
[Cp] Country of publication:Italy
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1007/s11739-018-1825-y

  7 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523958
[Au] Autor:Hayes W; Paglialonga F
[Ad] Address:Great Ormond Street Hospital, London, UK. Wesley.hayes@gosh.nhs.uk.
[Ti] Title:Assessment and management of fluid overload in children on dialysis.
[So] Source:Pediatr Nephrol;, 2018 Mar 09.
[Is] ISSN:1432-198X
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Dysregulation of intravascular fluid leads to chronic volume overload in children with end-stage kidney disease (ESKD). Sequelae include left ventricular hypertrophy and remodeling and impaired cardiac function. As a result, cardiovascular complications are the commonest cause of mortality in the pediatric dialysis population. The clinical need to optimize intravascular volume in children with ESKD is clear; however, its assessment and management is the most challenging aspect of the pediatric dialysis prescription. Minimizing chronic fluid overload is a key priority; however, excessive ultrafiltration is toxic to the myocardium and can precipitate intradialytic symptoms. This review outlines emerging objective techniques to enhance the assessment of fluid overload in children on dialysis and outlines evidence for current management strategies to address this clinical problem.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1007/s00467-018-3916-4

  8 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523944
[Au] Autor:Moreno-Montoro M; Jauregi P; Navarro-Alarcn M; Olalla-Herrera M; Gimnez-Martnez R; Amigo L; Miralles B
[Ad] Address:Department of Nutrition and Food Science, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071, Granada, Spain.
[Ti] Title:Bioaccessible peptides released by in vitro gastrointestinal digestion of fermented goat milks.
[So] Source:Anal Bioanal Chem;, 2018 Mar 10.
[Is] ISSN:1618-2650
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:In this study, ultrafiltered goat milks fermented with the classical starter bacteria Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus salivarus subsp. thermophilus or with the classical starter plus the Lactobacillus plantarum C4 probiotic strain were analyzed using ultra-high performance liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS) and/or high performance liquid chromatography-ion trap (HPLC-IT-MS/MS). Partial overlapping of the identified sequences with regard to fermentation culture was observed. Evaluation of the cleavage specificity suggested a lower proteolytic activity of the probiotic strain. Some of the potentially identified peptides had been previously reported as angiotensin-converting enzyme (ACE) inhibitory, antioxidant, and antibacterial and might account for the in vitro activity previously reported for these fermented milks. Simulated digestion of the products was conducted in the presence of a dialysis membrane to retrieve the bioaccessible peptide fraction. Some sequences with reported physiological activity resisted digestion but were found in the non-dialyzable fraction. However, new forms released by digestion, such as the antioxidant α -casein YFYPQL , the antihypertensive α -casein YQKFPQY , and the antibacterial α -casein LKKISQ , were found in the dialyzable fraction of both fermented milks. Moreover, in the fermented milk including the probiotic strain, the k-casein dipeptidyl peptidase IV inhibitor (DPP-IV) INNQFLPYPY as well as additional ACE inhibitory or antioxidant sequences could be identified. With the aim of anticipating further biological outcomes, quantitative structure activity relationship (QSAR) analysis was applied to the bioaccessible fragments and led to potential ACE inhibitory sequences being proposed. Graphical abstract Ultrafiltered goat milks were fermented with the classical starter bacteria (St) and with St plus the L. plantarum C4 probiotic strain. Samples were analyzed using HPLC-IT-MS/MS and UPLC-Q-TOF-MS/MS. After simulated digestion and dialysis, some of the active sequences remained and new peptides with reported beneficial activities were released.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1007/s00216-018-0983-0

  9 / 166816 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523884
[Au] Autor:Augeul-Meunier K; Chretien ML; Stoppa AM; Karlin L; Benboubker L; Diaz JMT; Mohty M; Yakoub-Agha I; Bay JO; Perrot A; Bulabois CE; Huynh A; Mercier M; Frenzel L; Avet-Loiseau H; de Latour RP; Cornillon J
[Ad] Address:Institut de Cancrologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
[Ti] Title:Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.
[So] Source:Bone Marrow Transplant;, 2018 Mar 09.
[Is] ISSN:1476-5365
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Renal impairment is a common complication of multiple myeloma (MM), accounting for 20-30% of MM patients at diagnosis and 40-50% of patients during the course of their disease. This feature is associated with poor prognosis and shorter survival as compared to patients with normal renal function (NRF). Therefore, therapeutic management is challenging as autologous stem cell transplantation (ASCT) is often not considered as a valuable strategy, mainly due to concerns of toxicity. In this retrospective and multicenter study, we included 55 MM patients with dialysis-dependent or independent renal failure who underwent high-dose melphalan-based ASCT in order to assess the efficacy outcomes and toxicities of this strategy. Response to ASCT was at least VGPR (very good PR) in 58% of patients and 96% of patients who also received bortezomib-based induction were at least in PR after ASCT. Median OS was 76 months and median PFS was 55 months, similarly to MM patients with NRF. In multivariate analysis, dose of melphalan (140 mg/m ) was correlated with better PFS (18 months, P = 0.005). Toxicities included febrile neutropenia (75%) and severe mucositis (34%). Overall, this work confirmed that ASCT conditioned by 140 mg/m melphalan is a beneficial procedure for MM patients with renal failure.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1038/s41409-018-0122-8

  10 / 166816 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29523679
[Au] Autor:Lau WL; Obi Y; Kalantar-Zadeh K
[Ad] Address:Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California, Irvine, California.
[Ti] Title:Parathyroidectomy in the Management of Secondary Hyperparathyroidism.
[So] Source:Clin J Am Soc Nephrol;, 2018 Mar 09.
[Is] ISSN:1555-905X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Secondary hyperparathyroidism develops in CKD due to a combination of vitamin D deficiency, hypocalcemia, and hyperphosphatemia, and it exists in nearly all patients at the time of dialysis initiation. There is insufficient data on whether to prefer vitamin D analogs compared with calcimimetics, but the available evidence suggests advantages with combination therapy. Calcium derangements, patient adherence, side effects, and cost limit the use of these agents. When parathyroid hormone level persists >800 pg/ml for >6 months, despite exhaustive medical interventions, monoclonal proliferation with nodular hyperplasia is likely present along with decreased expression of vitamin D and calcium-sensing receptors. Hence, surgical parathyroidectomy should be considered, especially if concomitant disorders exist, such as persistent hypercalcemia or hyperphosphatemia, tissue or vascular calcification including calciphylaxis, and/or worsening osteodystrophy. Parathyroidectomy is associated with 15%-57% greater survival in patients on dialysis, and it also improves hypercalcemia, hyperphosphatemia, tissue calcification, bone mineral density, and health-related quality of life. The parathyroidectomy rate in the United States declined to approximately seven per 1000 dialysis patient-years between 2002 and 2011 despite an increase in average parathyroid hormone levels, reflecting calcimimetics introduction and uncertainty regarding optimal parathyroid hormone targets. Hospitalization rates are 39% higher in the first postoperative year. Hungry bone syndrome occurs in approximately 25% of patients on dialysis, and profound hypocalcemia requires high doses of oral and intravenous calcium along with calcitriol supplementation. Total parathyroidectomy with autotransplantation carries a higher risk of permanent hypocalcemia, whereas risk of hyperparathyroidism recurrence is higher with subtotal parathyroidectomy. Given favorable long-term outcomes from observational parathyroidectomy cohorts, despite surgical risk and postoperative challenges, it is reasonable to consider parathyroidectomy in more patients with medically refractory secondary hyperparathyroidism.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher


page 1 of 16682 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information